New hope for dialysis patients: drug targets both phosphorus and cholesterol
NCT ID NCT00542386
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tested a drug called MCI-196 in 642 adults on dialysis who had high phosphorus and cholesterol levels. Participants took either the drug or a placebo for 12 weeks to see if it could safely lower these levels. The goal was to help manage heart and bone risks in people with advanced kidney disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Ajka, Hungary
-
Study site
Baja, Hungary
-
Study site
Budapest, Hungary
-
Study site
Esztergom, Hungary
-
Study site
Győr, Hungary
-
Study site
Hatvan, Hungary
-
Study site
Kisvárda, Hungary
-
Study site
Lecco, Italy
-
Study site
Modena, Italy
-
Study site
Pavia, Italy
-
Study site
Roma, Italy
-
Study site
Alor Star, Malaysia
-
Study site
Ipoh, Malaysia
-
Study site
Kajang, Malaysia
-
Study site
Klang, Malaysia
-
Study site
Kota Kinabalu, Malaysia
-
Study site
Kuala Terengganu, Malaysia
-
Study site
Kuantan, Malaysia
-
Study site
Kuching, Malaysia
-
Study site
Malacca, Malaysia
-
Study site
Seremban, Malaysia
-
Study site
Taiping, Malaysia
-
Study site
Skopje, North Macedonia
-
Study site
Lodz, Poland
-
Study site
Poznan, Poland
-
Study site
Płock, Poland
-
Study site
Rybnik, Poland
-
Study site
Warsaw, Poland
-
Study site
Wroclaw, Poland
-
Study site
Zielona Góra, Poland
-
Study site
Arkhangelsk, Russia
-
Study site
Armavir, Russia
-
Study site
Chelyabinsk, Russia
-
Study site
Chita, Russia
-
Study site
Irkutsk, Russia
-
Study site
Ivanovo, Russia
-
Study site
Kaluga, Russia
-
Study site
Kemerovo, Russia
-
Study site
Khabarovsk, Russia
-
Study site
Krasnodar, Russia
-
Study site
Krasnoyarsk, Russia
-
Study site
Moscow, Russia
-
Study site
Nizhny Novgorod, Russia
-
Study site
Novokuznetsk, Russia
-
Study site
Novorossiysk, Russia
-
Study site
Novosibirsk, Russia
-
Study site
Omsk, Russia
-
Study site
Petrozavodsk, Russia
-
Study site
Rostov-on-Don, Russia
-
Study site
Saint Petersburg, Russia
-
Study site
Smolensk, Russia
-
Study site
Tomsk, Russia
-
Study site
Tver', Russia
-
Study site
Tyumen, Russia
-
Study site
Vladimir, Russia
-
Study site
Vladivostok, Russia
-
Study site
Volzhskiy, Russia
-
Study site
Yaroslavl, Russia
-
Study site
Yekaterinburg, Russia
-
Study site
Belgrade, Serbia
-
Study site
Kragujevac, Serbia
-
Study site
Niš, Serbia
-
Study site
Novi Sad, Serbia
-
Study site
Chernivtsi, Ukraine
-
Study site
Dnipro, Ukraine
-
Study site
Ivano-Frankivsk, Ukraine
-
Study site
Kharkiv, Ukraine
-
Study site
Kiev, Ukraine
-
Study site
Mykolaiv, Ukraine
-
Study site
Ternopil, Ukraine
-
Study site
Uzhhorod, Ukraine
-
Study site
Zaporizhya, Ukraine
-
Study site
Zhytomyr, Ukraine
Conditions
Explore the condition pages connected to this study.